

Clinical Trial Protocol

Iranian Registry of Clinical Trials

14 Jul 2026

Comparison of the effect of diazepam alone and in combination with haloperidol in controlling agitation caused by stimulants

Protocol summary

Study aim

Comparison of the effect of diazepam alone and in combination with haloperidol in controlling agitation caused by stimulants

Design

The method of randomization is the use of black and white beads. In this method, the black bead will be the intervention group and the white bead will be the control group. blind on both sides

Settings and conduct

The research population is those patients referred to the emergency department of hospitals affiliated to Shahid Beheshti University of Medical Sciences, who referred to this center in 1401 for the treatment of agitation caused by stimulants, according to this, all these patients were not randomized. Asan is considered as a study group in the intervention and control group. After the desired patients (N=60) were selected, the randomization method is using black and white beads. In this method, the black bead will be the intervention group and the white bead will be the control group. In the continuation of the treatment of the patients, in the diazepam group, this drug will be used with a dose of 10 mg, and in the diazepam (10 mg) + haloperidol (5 mg) group, this drug will be used. In order to evaluate the state of restlessness and relaxation, the Richmond 3 index will be used.

Participants/Inclusion and exclusion criteria

Entry criteria: over 18 years old. Exclusion criteria: lack of consent to participate in the study, presence of risk factors for cognitive disorders such as brain and nerve disease, history of moderate to severe head trauma, history of head trauma, decreased level of consciousness, glaucoma, psychosis, moderate to severe substance dependence Other, heart diseases such as long QT 2 and observing side effects of used drugs

Intervention groups

Diazepam group, from this drug with a dose of 10 mg and diazepam group (10 mg) + haloperidol (5 mg)

Main outcome variables

agitation

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20210720051946N6**

Registration date: **2024-01-07, 1402/10/17**

Registration timing: **registered_while_recruiting**

Last update: **2024-01-07, 1402/10/17**

Update count: **0**

Registration date

2024-01-07, 1402/10/17

Registrant information

Name

Peyman Erfan Talab Evini

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 5102 5000

Email address

peyman1346erfan@sbmu.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-12-14, 1402/09/23

Expected recruitment end date

2024-03-19, 1402/12/29

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison of the effect of diazepam alone and in combination with haloperidol in controlling agitation caused by stimulants

Public title

Effect of diazepam and haloperidol in controlling agitation

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Inclusion criteria include consent to participate in the study, diagnosis of agitation with DSM 5 1 criteria following the consumption of stimulants and age over 18 years.

Exclusion criteria:

On the other hand, another set of indicators is considered as exclusion criteria, these exclusion criteria include lack of consent to participate in the study, the presence of risk factors for cognitive disorders such as the presence of brain and nerve diseases (such as seizures, dementia, Parkinson's), a history of moderate to severe head trauma, a history of head trauma, decreased level of consciousness, glaucoma, psychosis, moderate to severe dependence on other substances, heart diseases such as long QT 2, and observation of the side effects of the drugs used.

Age

From 18 years old

Gender

Both

Phase

0

Groups that have been masked

- Participant
- Outcome assessor

Sample size

Target sample size: 60

Randomization (investigator's opinion)

Randomized

Randomization description

After the desired patients (N=60) were selected, the patients were randomly and double-blindly divided into intervention and control groups. The randomization method was the use of black and white beads. In this method, the black bead will be the intervention group and the white bead will be the control group. Also, in order to blind the patients, they will be blinded to the other group. In the continuation of the treatment of the patients, in the diazepam group, this drug will be used with a dose of 10 mg, and in the diazepam (10 mg) + haloperidol (5 mg) group, this drug will be used. In the following, to evaluate the level of agitation, the evaluation of the level of sedation is used and its level is determined.

Blinding (investigator's opinion)

Double blinded

Blinding description

After the desired patients (N=60) were selected, the patients were randomly and double-blindly divided into intervention and control groups. The randomization method was the use of black and white beads. In this method, the black bead will be the intervention group and the white bead will be the control group. Also, in order to blind the patients, they will be blinded to the other group. In the continuation of the treatment of the patients, in the diazepam group, this drug will be used with a dose of 10 mg, and in the diazepam (10 mg) + haloperidol (5 mg) group, this drug will be used. In the following, to evaluate the level of agitation, the evaluation of the level of sedation is used and its level is determined.

Placebo

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Shahid Beheshti University of Medical Sciences

Street address

Velenjak Square, Daneshju Blv

City

Tehran

Province

Tehran

Postal code

1983969411

Approval date

2023-11-19, 1402/08/28

Ethics committee reference number

IR.SBMU.RETECH.REC.1402.451

Health conditions studied**1****Description of health condition studied**

poisoned patients

ICD-10 code

F00-F99

ICD-10 code description

F00-F99

Primary outcomes**1****Description**

agitation
Timepoint
0,10,15,30 min
Method of measurement
richmond questionnaire

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: Diazepam (10 mg) + Haloperidol (5 mg)

Category

Treatment - Drugs

2

Description

Control group: Diazepam (10 mg)

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Loghman Hospital

Full name of responsible person

Peyman Erfan Talab Evini

Street address

Kamali Street

City

Tehran

Province

Tehran

Postal code

1333631151

Phone

+98 21 5541 9005

Email

peyman1346erfan@sbm.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Peyman Erfan Talab Evini

Street address

Velenjak Square

City

Tehran

Province

Tehran

Postal code

1985717443

Phone

+98 21 23871

Email

peyman1346erfan@sbm.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Shahid Beheshti University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Peyman Erfan Talab Evini

Position

Assistant professor

Latest degree

Subspecialist

Other areas of specialty/work

Toxicology

Street address

Kamali Street

City

Tehran

Province

Tehran

Postal code

1333631151

Phone

+98 21 5102 5000

Email

peyman1346erfan@sbm.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Peyman Erfan Talab Evini

Position

Assistant Professor
Latest degree
Subspecialist
Other areas of specialty/work
Toxicology
Street address
Kamali Street
City
Tehran
Province
Tehran
Postal code
1333631151
Phone
+98 21 5541 9005
Email
peyman1346erfan@sbmu.ac.ir

Person responsible for updating data

Contact

Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Peyman Erfan Talab Evini
Position
Assistant professor
Latest degree
Subspecialist
Other areas of specialty/work
Toxicology
Street address
Kamali Street
City
Tehran
Province
Tehran
Postal code
1333631151

Phone
+98 21 5541 9005
Email
peyman1346erfan@sbmu.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

All data is potentially shareable after de-identifying individuals

When the data will become available and for how long

The access period starts from the year 2024

To whom data/document is available

Researchers working in academic and scientific institutions

Under which criteria data/document could be used

People who are also engaged in pharmaceuticals and research

From where data/document is obtainable

Peyman Erfan Talab Evini

What processes are involved for a request to access data/document

Administrative correspondence seven to ten working days

Comments